*Doses are commonly-reported figures from public sources, not a recommendation. Educational only.
| Year | Title / venue | Source |
|---|---|---|
| 2025 | Nociceptor neurons suppress alveolar macrophage-induced Siglec-F(+) neutrophil-mediated inflammation to protect against pulmonary fibrosis Immunity · preclinical | PMID 40449484 |
| 2025 | Proinflammatory cytokines and neuropeptides in psoriasis, depression, and anxiety Acta physiologica (Oxford, England) · preclinical | PMID 39960105 |
| 2023 | The role of vasoactive intestinal peptide in pulmonary diseases Life sciences · preclinical | PMID 37742737 |
| 2023 | Whole genome sequencing identifies genetic variants associated with neurogenic inflammation in rosacea Nature communications · preclinical | PMID 37402769 |
| 2022 | Immunomodulatory effect of N-acetyl-seryl-aspartyl-proline and vasoactive intestinal peptide on chronic obstructive pulmonary disease pathophysiology Fundamental & clinical pharmacology · preclinical | PMID 35763864 |
| 2021 | Neuroimmune Pathophysiology in Asthma Frontiers in cell and developmental biology · preclinical | PMID 34055794 |
| 2018 | Skin neurogenic inflammation Seminars in immunopathology · preclinical | PMID 29713744 |
| 2018 | Vasoactive intestinal peptide is upregulated in women with endometriosis and chronic pelvic pain American journal of reproductive immunology (New York, N.Y. : 1989) · preclinical | PMID 29675846 |
| 2017 | Vasoactive intestinal peptide dampens formyl-peptide-induced ROS production and inflammation by targeting a MAPK-p47(phox) phosphorylation pathway in monocytes Mucosal immunology · preclinical | PMID 27271317 |
| 2015 | Silencing Nociceptor Neurons Reduces Allergic Airway Inflammation Neuron · preclinical | PMID 26119026 |
| 2015 | The neuropeptide vasoactive intestinal peptide: direct effects on immune cells and involvement in inflammatory and autoimmune diseases Acta physiologica (Oxford, England) · preclinical | PMID 25422088 |
| 2013 | Type 2 innate lymphoid cells control eosinophil homeostasis Nature · preclinical | PMID 24037376 |
| 2011 | Prospect of vasoactive intestinal peptide therapy for COPD/PAH and asthma: a review Respiratory research · preclinical | PMID 21477377 |
| 2009 | Expression of vasoactive intestinal peptide and related receptors in overcirculation-induced pulmonary hypertension in piglets Pediatric research · preclinical | PMID 19581838 |
| 2005 | Role of vasoactive intestinal peptide in inflammation and autoimmunity Current opinion in investigational drugs (London, England : 2000) · preclinical | PMID 16312132 |
| 2004 | Role of vasoactive intestinal peptide and inflammatory mediators in enteric neuronal plasticity Neurogastroenterology and motility · preclinical | PMID 15066017 |
| 2000 | Pathways of inflammation and cell death in the lung: modulation by vasoactive intestinal peptide Regulatory peptides · preclinical | PMID 11033049 |
| 1991 | Neuropeptides and asthma The American review of respiratory disease · preclinical | PMID 1706152 |
VIP (Vasoactive Intestinal Peptide). 28-amino-acid neuropeptide with vasodilatory, immunomodulatory, and anti-inflammatory actions via VPAC1/VPAC2 receptors; studied in chronic inflammatory response syndrome (CIRS) and pulmonary hypertension research.
Commonly discussed uses: CIRS/mould-illness protocols (anecdotal/some clinical use intranasal), pulmonary/anti-inflammatory research. There is both human and animal/preclinical research, though the depth and quality vary by indication. Note: most uses are not approved indications.
Mechanism: 28-amino-acid neuropeptide with vasodilatory, immunomodulatory, and anti-inflammatory actions via VPAC1/VPAC2 receptors; studied in chronic inflammatory response syndrome (CIRS) and pulmonary hypertension research.
Reported considerations: hypotension/flushing (vasodilatory), limited controlled human data. There is both human and animal/preclinical research, though the depth and quality vary by indication. Not approved; compounded use in niche protocols. Controlled efficacy evidence is limited. This is not a safety endorsement; safety data for unapproved compounds is incomplete.
Commonly cited ranges (educational reference, not a recommendation): low 50mcg intranasal, typical intranasal 50mcg several x/day (Shoemaker-protocol-style), high protocol-defined. Administration: intranasal, subcutaneous (research), inhaled (research). Half-life: very short (~1-2 min systemic).
Australian status: Not ARTG-registered; compounded with prescription. Not approved; compounded use in niche protocols. Controlled efficacy evidence is limited. General regulatory context: most active peptides are Schedule 4 and require a prescription; import via the Personal Importation Scheme requires a valid Australian prescription for prescription-only goods.
Reconstitution/storage reference: compounded intranasal formulation varies; storage: refrigerated.
Commonly discussed combinations (anecdotal for unapproved compounds): intranasal VIP standalone (CIRS protocols, anecdotal). Stacking increases interaction/safety uncertainty.